Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Biosimilar Monoclonal Antibodies Market From 2025 To 2029?

The market size of biosimilar monoclonal antibodies has seen a quick expansion in the previous years and is expected to rise from $8.04 billion in 2024 to $9.25 billion in 2025, growing at a compound annual rate (CAGR) of 15.1%. Factors contributing to this growth over the past years include expiry of patents, heightened Biosimilars awareness, government-led initiatives, increased funding by pharmaceutical organizations, and a rise in the acceptance of Biosimilars by medical practitioners and patients.

What Is the Projected Market Size of the Biosimilar Monoclonal Antibodies Market?

In the forthcoming years, the biosimilar monoclonal antibodies market is projected to witness robust growth. It is predicted to reach a valuation of $12.79 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%. This predicted growth during the forecast period can be credited to factors like increasing biologic spending, expansion of biosimilar portfolio, customizing biosimilar therapy, and growing public intrigue in biosimilars. The anticipated trends throughout this period comprise of therapeutic expansion, individualized biosimilars, alliances and partnerships, biosimilar autoinjectors and devices, and biobetters.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp

Who are the Major Competitors in the Biosimilar Monoclonal Antibodies Market Outlook?

Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

What Is Fueling Growth in the Biosimilar Monoclonal Antibodies Market?

Chronic diseases’ rising occurrence is projected to fuel the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies address chronic conditions such as cancer, autoimmune diseases, and rheumatoid arthritis. Biosimilar versions of monoclonal antibodies like trastuzumab, bevacizumab, and rituximab are utilized in cancer therapy. Furthermore, cancer incidence is on an upward trend annually. For example, reports from the U.S.-based public health agency, the Centers for Disease Control and Prevention (CDC), in February 2024 indicated an increasing number of Americans dealing with multiple chronic diseases, with 42% managing two or more, and 12% coping with five or more. Hence, the surge in chronic diseases is projected to prompt the expansion of the biosimilar monoclonal antibodies market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3412&type=smp

Which Biosimilar Monoclonal Antibodies Market Segments Are Growing the Fastest?

The biosimilar monoclonal antibodies market covered in this report is segmented –

1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types

2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications

Subsegments:

1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products

2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals

3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics

Which Industry Trends Are Shaping the Future of the Biosimilar Monoclonal Antibodies Market?

Prominent businesses in the biosimilar monoclonal antibodies market are concentrating their efforts on creating economical biosimilar therapies in order to maintain a competitive edge. These therapies are biologic medical products that closely resemble previously approved reference monoclonal antibodies, intended to provide cost-effective treatment alternatives for a range of diseases such as cancer and autoimmune disorders. To illustrate, in 2022, Pfizer, a pharmaceutical corporation based in the United States, introduced Abrilada, a biosimilar of AbbVie’s Humira (adalimumab). Abrilada possesses a safety and efficacy profile equivalent to the original, but with substantial cost reductions for both patients and healthcare systems. Additionally, it takes advantage of streamlined approval procedures and strong manufacturing facilities, increasing patient access to vital treatments. This pattern signifies a wider shift in the industry to tackle escalating healthcare costs while continuing to provide superior therapeutic choices for patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Which Countries Are Leading the Biosimilar Monoclonal Antibodies Market?

The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3412

This Report Delivers Insight On:

1. How big is the biosimilar monoclonal antibodies market, and how is it changing globally?

2. Who are the major companies in the biosimilar monoclonal antibodies market, and how are they performing?

3. What are the key opportunities and risks in the biosimilar monoclonal antibodies market right now?

4. Which products or customer segments are growing the most in the biosimilar monoclonal antibodies market?

5. What factors are helping or slowing down the growth of the biosimilar monoclonal antibodies market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model